Health · 1 views
Targeting cell division protein CDK2 could boost immunotherapy response across a wide range of cancers
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be m…
Summary
Cell (2026). DOI: 10.1016/j.molcel.2026.08.007 New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Mental health groups have ‘failed to acknowledge’ risk of violence, says Mind chiefContinue reading
- Activation of community first responders did not improve short-term survival after cardiac arrestContinue reading
- Study identifies key driver of inflammation, opening door to potential new treatmentsContinue reading
- Evidence points to yogurt as a nutrient-dense part of healthy dietsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow